Global MENA Biologics & Biosimilars Market Is Estimated To Witness High Growth Owing To Increasing Demand for Advanced Biologic Drugs
MENA Biologics & Biosimilars Market |
The global MENA Biologics & Biosimilars Market is estimated to be valued at US$ 442.5 Mn in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights.
A) Market Overview:
The MENA Biologics & Biosimilars market refers to the market for biologic
drugs and biosimilars in the Middle East and North Africa region. Biologic
drugs are complex therapeutic proteins that are produced by living organisms
using biotechnology. These drugs have revolutionized the treatment of various
diseases, including cancer, autoimmune disorders, and chronic diseases.
Biosimilars are highly similar versions of biologic drugs, which are developed
after the expiration of the patent protection of the original biologic drug.
The need for biologic drugs and biosimilars arises from the increasing
prevalence of chronic diseases and the demand for more targeted and effective
treatment options. Biologic drugs provide better efficacy and fewer side
effects compared to traditional small molecule drugs. Biosimilars, on the other
hand, offer cost savings and increased access to these life-saving therapies.
B) Market Key Trends:
One key trend in the MENA
Biologics & Biosimilars market is the increasing adoption of
biosimilars by healthcare providers and patients. Biosimilars offer significant
cost savings compared to their reference biologic drugs, making them an
attractive option for healthcare systems striving to reduce healthcare costs.
The increasing acceptance and confidence in the safety and efficacy of
biosimilars among physicians and patients are driving their adoption in the
MENA region.
For example, in Saudi Arabia, the Ministry of Health has implemented a national
policy promoting the use of biosimilars in order to reduce healthcare costs and
improve patient access. This policy has led to an increased uptake of
biosimilars in the country.
C) PEST Analysis:
Political: The MENA region is characterized by varying political landscapes,
with some countries experiencing political instability and conflicts. These
factors can impact the market growth and regulatory environment for biologic
drugs and biosimilars.
Economic: The economic growth and healthcare expenditure in the MENA region are
increasing, which creates opportunities for the biologics and biosimilars
market. However, affordability and reimbursement challenges may hinder market
growth.
Social: The increasing prevalence of chronic diseases, aging population, and
growing awareness among patients about advanced treatment options are driving
the demand for biologic drugs and biosimilars in the MENA region.
Technological: Advancements in biotechnology and manufacturing techniques have
led to the development of complex biologic drugs and biosimilars. These
technological advancements enable the production of high-quality and
cost-effective biologic drugs, facilitating market growth.
D) Key Takeaways:
Paragraph 1: The MENA Biologics & Biosimilars market is expected to witness
high growth, exhibiting a CAGR of 3.9% over the forecast period. This growth is
attributed to the increasing demand for advanced biologic drugs and
biosimilars. The need for targeted and effective treatments for chronic
diseases is driving the market.
Paragraph 2: The Middle East region is expected to be the fastest-growing and
dominating region in the MENA Biologics & Biosimilars market. The region is
witnessing increased government initiatives to promote the use of biosimilars,
resulting in their higher adoption.
Paragraph 3: Key players operating in the MENA Biologics & Biosimilars
market include F. Hoffmann-la Roche Ag, Regeneron Pharmaceuticals, Inc.,
Pfizer, Inc., Amgen, Inc., Sanofi S.A., and Takeda Pharmaceutical Company
Limited. These companies are actively involved in research and development
activities to introduce innovative biologic drugs and biosimilars in the
market.
In conclusion, the MENA Biologics & Biosimilars market is poised for
significant growth due to the increasing demand for advanced biologic drugs and
biosimilars. The adoption of biosimilars is on the rise in the region, driven
by cost savings and improving confidence in their efficacy and safety. However,
challenges related to affordability and reimbursement may hinder market growth.
Key players in the market are focusing on research and development to introduce
innovative products and capture a larger market share.
Comments
Post a Comment